Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Laura Michaelis MD

Laura Michaelis MD profile photo picture

Chief, Professor

Institution: Medical College of Wisconsin
Department: Medicine
Division: Hematology and Oncology - Medicine
Program: Hematology

Member of the Cancer Center

Publications (27)

  • Venetoclax in AML: aiming for "just right". (Michaelis LC) Blood 2019 Jan 03;133(1):3-4 PMID: 30606807 SCOPUS ID: 2-s2.0-85059500759 01/05/2019       3 Citations
  • Advancements in the management of medically less-fit and older adults with newly diagnosed acute myeloid leukemia. (Michaelis LC, Klepin HD, Walter RB) Expert Opin Pharmacother 2018 Jun;19(8):865-882 PMID: 29697000 SCOPUS ID: 2-s2.0-85047964670 04/27/2018       14 Citations
  • Early Fluorescence in situ Hybridization Assessment during Acute Myeloid Leukemia Induction Chemotherapy. (Schneidewend R, Hosking P, Brazauskas R, Peterson J, Beaudin C, Michaelis L, Atallah E, Hari P, Carlson K) Acta Haematol 2018;139(3):171-175 PMID: 29597188 PMCID: PMC6388419 SCOPUS ID: 2-s2.0-85045039013 03/30/2018    
  • Report of the relapsed/refractory cohort of SWOG S0919: A phase 2 study of idarubicin and cytarabine in combination with pravastatin for acute myelogenous leukemia (AML). (Advani AS, Li H, Michaelis LC, Medeiros BC, Liedtke M, List AF, O'Dwyer K, Othus M, Erba HP, Appelbaum FR) Leuk Res 2018 Apr;67:17-20 PMID: 29407182 PMCID: PMC6574123 SCOPUS ID: 2-s2.0-85041670448 02/07/2018       20 Citations
  • Intergroup LEAP trial (S1612): A randomized phase 2/3 platform trial to test novel therapeutics in medically less fit older adults with acute myeloid leukemia. (Walter RB, Michaelis LC, Othus M, Uy GL, Radich JP, Little RF, Hita S, Saini L, Foran JM, Gerds AT, Klepin HD, Hay AE, Assouline S, Lancet JE, Couban S, Litzow MR, Stone RM, Erba HP) Am J Hematol 2018 Feb;93(2):E49-E52 PMID: 29164656 PMCID: PMC5760282 SCOPUS ID: 2-s2.0-85037372411 11/23/2017       12 Citations
  • Current challenges in the management of essential thrombocythemia. (Kleman A, Singavi AK, Michaelis LC) Clin Adv Hematol Oncol 2017 Oct;15(10):773-783 PMID: 29040257 SCOPUS ID: 2-s2.0-85033804556 10/19/2017       8 Citations
  • A Fatal Case of Erdheim-Chester Disease with Hepatic Involvement. (Balasubramanian G, Modiri A, Affi M, Hagen CE, Batdorf B, Oshima K, Michaelis L, Saeian K) ACG Case Rep J 2017;4:e95 PMID: 28798943 PMCID: PMC5541758 08/12/2017    
  • Early mortality in patients with acute myelogenous leukemia treated in teaching versus non-teaching hospitals: A large database analysis. (Levin A, Kleman A, Rein L, Tarima S, Michaelis LC, Carlson KS, Hamadani M, Fenske TS, Hari P, Atallah E, Dhakal B) Am J Hematol 2017 Sep;92(9):E563-E565 PMID: 28631379 SCOPUS ID: 2-s2.0-85021972988 06/21/2017       4 Citations
  • Recipient Immune Modulation with Atorvastatin for Acute Graft-versus-Host Disease Prophylaxis after Allogeneic Transplantation. (Kanate AS, Hari PN, Pasquini MC, Visotcky A, Ahn KW, Boyd J, Guru Murthy GS, Rizzo JD, Saber W, Drobyski W, Michaelis L, Atallah E, Carlson KS, D'Souza A, Fenske TS, Cumpston A, Bunner P, Craig M, Horowitz MM, Hamadani M) Biol Blood Marrow Transplant 2017 Aug;23(8):1295-1302 PMID: 28412518 SCOPUS ID: 2-s2.0-85019639994 04/17/2017       7 Citations
  • Risk stratification in myelofibrosis: the quest for simplification. (Michaelis LC) Haematologica 2017 Jan;102(1):2-3 PMID: 28040786 PMCID: PMC5210226 SCOPUS ID: 2-s2.0-85008319087 01/04/2017       3 Citations
  • Safety of ruxolitinib therapy prior to allogeneic hematopoietic stem-cell transplantation for myeloproliferative neoplasms. (Hanif A, Hari PN, Atallah E, Carlson KS, Pasquini MC, Michaelis LC) Bone Marrow Transplant 2016 Apr;51(4):617-8 PMID: 26726940 SCOPUS ID: 2-s2.0-84953295752 01/05/2016       16 Citations
  • Outcomes of Allogeneic Hematopoietic Cell Transplantation in┬áPatients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors. (Shanavas M, Popat U, Michaelis LC, Fauble V, McLornan D, Klisovic R, Mascarenhas J, Tamari R, Arcasoy MO, Davies J, Gergis U, Ukaegbu OC, Kamble RT, Storring JM, Majhail NS, Romee R, Verstovsek S, Pagliuca A, Vasu S, Ernst B, Atenafu EG, Hanif A, Champlin R, Hari P, Gupta V) Biol Blood Marrow Transplant 2016 Mar;22(3):432-40 PMID: 26493563 PMCID: PMC5030817 SCOPUS ID: 2-s2.0-84950996639 10/24/2015       109 Citations
  • Recent developments in the treatment of older individuals with acute myeloid leukemia: 2014. (Michaelis LC, Erba HP) Curr Opin Hematol 2015 Mar;22(2):108-15 PMID: 25603478 SCOPUS ID: 2-s2.0-84923248544 01/21/2015       6 Citations
  • Mechanisms of thrombogenesis in polycythemia vera. (Kroll MH, Michaelis LC, Verstovsek S) Blood Rev 2015 Jul;29(4):215-21 PMID: 25577686 PMCID: PMC4466074 SCOPUS ID: 2-s2.0-84937164094 01/13/2015       50 Citations
  • Hematopoietic stem cell transplantation in older persons: respecting the heterogeneity of age. (Michaelis LC, Hamadani M, Hari PN) Expert Rev Hematol 2014 Jun;7(3):321-4 PMID: 24785114 SCOPUS ID: 2-s2.0-84900867182 05/03/2014       8 Citations
  • Cutis verticis gyrata. (Walshauser MA, Birch NW, Michaelis LC) Am J Med Sci 2014 Aug;348(2):176 PMID: 23328837 SCOPUS ID: 2-s2.0-84905094221 01/19/2013       3 Citations
  • Salvage second hematopoietic cell transplantation in myeloma. (Michaelis LC, Saad A, Zhong X, Le-Rademacher J, Freytes CO, Marks DI, Lazarus HM, Bird JM, Holmberg L, Kamble RT, Kumar S, Lill M, Meehan KR, Saber W, Schriber J, Tay J, Vogl DT, Wirk B, Savani BN, Gale RP, Vesole DH, Schiller GJ, Abidi M, Anderson KC, Nishihori T, Kalaycio ME, Vose JM, Moreb JS, Drobyski W, Munker R, Roy V, Ghobadi A, Holland HK, Nath R, To LB, Maiolino A, Kassim AA, Giralt SA, Landau H, Schouten HC, Maziarz RT, Mikhael J, Kindwall-Keller T, Stiff PJ, Gibson J, Lonial S, Krishnan A, Dispenzieri A, Hari P, Plasma Cell Disorders Working Committee of the Center for International Blood and Marrow Transplant Research) Biol Blood Marrow Transplant 2013 May;19(5):760-6 PMID: 23298856 PMCID: PMC3816739 SCOPUS ID: 2-s2.0-84876327529 01/10/2013       91 Citations
  • Age-related differences in disease characteristics and clinical outcomes in polycythemia vera. (Stein BL, Saraf S, Sobol U, Halpern A, Shammo J, Rondelli D, Michaelis L, Odenike O, Rademaker A, Zakarija A, McMahon B, Spivak JL, Moliterno AR) Leuk Lymphoma 2013 Sep;54(9):1989-95 PMID: 23245211 SCOPUS ID: 2-s2.0-84879104781 12/19/2012       57 Citations
  • Hemoglobin levels triggering erythropoiesis-stimulating agent therapy in patients with cancer: the shift after United States Food and Drug Administration policy changes. (Stroupe KT, Tarlov E, Lee TA, Weichle TW, Zhang QL, Michaelis LC, Ozer H, Durazo-Arvizu R, Browning MM, Hynes DM) Pharmacotherapy 2012 Nov;32(11):988-97 PMID: 23108695 SCOPUS ID: 2-s2.0-84871581983 10/31/2012       5 Citations
  • Trends in anemia management in lung and colon cancer patients in the US Department of Veterans Affairs, 2002-2008. (Tarlov E, Stroupe KT, Lee TA, Weichle TW, Zhang QL, Michaelis LC, Ozer H, Browning MM, Hynes DM) Support Care Cancer 2012 Aug;20(8):1649-57 PMID: 21935718 SCOPUS ID: 2-s2.0-84863989608 09/22/2011       14 Citations
  • Rearrangements of the MLL gene are influenced by DNA secondary structure, potentially mediated by topoisomerase II binding. (Le H, Singh S, Shih SJ, Du N, Schnyder S, Loredo GA, Bien C, Michaelis L, Toor A, Diaz MO, Vaughan AT) Genes Chromosomes Cancer 2009 Sep;48(9):806-15 PMID: 19530238 PMCID: PMC2764312 SCOPUS ID: 2-s2.0-68549135307 06/17/2009       32 Citations
  • Hydroxyurea, azacitidine and gemtuzumab ozogamicin therapy in patients with previously untreated non-M3 acute myeloid leukemia and high-risk myelodysplastic syndromes in the elderly: results from a pilot trial. (Nand S, Godwin J, Smith S, Barton K, Michaelis L, Alkan S, Veerappan R, Rychlik K, Germano E, Stiff P) Leuk Lymphoma 2008 Nov;49(11):2141-7 PMID: 19021057 SCOPUS ID: 2-s2.0-57049171822 11/21/2008       58 Citations
  • Successful autologous stem cell collection in patients with chronic myeloid leukemia in complete cytogenetic response, with quantitative measurement of BCR-ABL expression in blood, marrow, and apheresis products. (Gordon MK, Sher D, Karrison T, Kebriaei P, Chuang K, Zhang Y, McDonnell D, Artz A, Godley L, Odenike O, Rich E, Michaelis L, Thirman MJ, Wickrema A, van Besien K, Larson RA, Stock W) Leuk Lymphoma 2008 Mar;49(3):531-7 PMID: 18297531 SCOPUS ID: 2-s2.0-39749131562 02/26/2008       8 Citations
  • Chimerism does not predict for outcome after alemtuzumab based conditioning. (Michaelis L, Lin S, Joseph L, Artz AS, Kline J, Pollyea D, Stock W, Rich E, Collins-Jones D, Casey B, Del Cerro P, van Besien K) Bone Marrow Transplant 2007 Jul;40(2):181 PMID: 17502895 SCOPUS ID: 2-s2.0-34447284249 05/16/2007       7 Citations
  • Phase II trials published in 2002: a cross-specialty comparison showing significant design differences between oncology trials and other medical specialties. (Michaelis LC, Ratain MJ) Clin Cancer Res 2007 Apr 15;13(8):2400-5 PMID: 17438099 SCOPUS ID: 2-s2.0-34247860864 04/18/2007       27 Citations
  • Measuring response in a post-RECIST world: from black and white to shades of grey. (Michaelis LC, Ratain MJ) Nat Rev Cancer 2006 May;6(5):409-14 PMID: 16633367 SCOPUS ID: 2-s2.0-33646357786 04/25/2006       163 Citations
  • Randomized phase II trials and prostate-specific antigen endpoints in prostate cancer: much ado about nothing? (Stadler WM, Michaelis LC, Ratain MJ) J Clin Oncol 2005 Nov 01;23(31):8124-5; author reply 8125-6 PMID: 16258115 SCOPUS ID: 2-s2.0-32944469067 11/01/2005       2 Citations
  • Last update: 11/13/2022